Dietary Intervention With Únicla Dairy Products (DANTIAN)

NCT ID: NCT05019118

Last Updated: 2021-08-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-06

Study Completion Date

2022-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dietary intervention with Únicla dairy products, naturally enriched with selenium and omega-3 fatty acids, may improve thyroid-stimulating hormone (TSH) levels in women with subclinical hypothyroidism

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To analyze in women diagnosed with subclinical hypothyroidism, the effects of consumption of dairy products rich in selenium and omega-3 on symptoms related to thyroid disease and blood lipid profile, inflammatory response, and fatty acid levels in the red blood cell membrane among others.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subclinical Hypothyroidism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, masked and controlled nutritional intervention study
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
The masking process will be triple blind, that is, both the participating women, the research staff (including those in charge of delivering the products and the one who performs and interprets the measurements), as well as the analyst, won't know at any time what group belong to patients. All the products in the study (Únicla dairy) as well as their respective placebos (conventional FEIRACO equivalent products) will maintain a similar format and labeling, with the organoleptic characteristics of dairy products being very similar. Masking will be opened at the time that the last data interpretation of the last subject included was made and before starting the statistical analysis

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention/treatment

Dairy foods made with UNICLA milk Participants (n = 45) ingested UNICLA milk and dairy products (yogurt and cheese) for three months.

UNICLA milk is characterised by an improved nutritional composition, obtained by modifying cow's diet, feeeding the dairy cows with a sufficient and balanced ration, which recreates the fatty acid profile of the spring.

This ration includes pastures, high-quality forages and, among other components, a significant amount of flax seeds, which constitute a source of unsaturated fatty acids such as omega-3 and selenised yeast, as a source of organic selenium.

Consequently, UNICLA milk and dairy products are naturally enriched in selenium and ω-3 PUFA.

The daily intake reflects the usual consumption habits, being the recommended amounts of 200 ml of milk and 125 g of yogurt per day and 400g of fresh cheese per week

Group Type EXPERIMENTAL

Experimental milk

Intervention Type OTHER

UNICLA milk naturally enriched in selenium and omega-3.

Experimental yogur

Intervention Type OTHER

UNICLA yogur naturally enriched in selenium and omega-3.

Experimental fresh cheese

Intervention Type OTHER

UNICLA fresh cheese naturally enriched in selenium and omega-3.

Conventional milk

Participants (n = 45) ingest milk and conventional dairy products daily for 3 months.

Daily intake reflects usual dairy consumption habits in "real life" conditions, without forcing or inducing increased consumption. Therefore, the recommended amounts are 200 ml of milk and 125 g of yogurt per day and 400 g of fresh cheese per week

Group Type PLACEBO_COMPARATOR

Placebo milk

Intervention Type OTHER

Conventional milk

Placebo yogur

Intervention Type OTHER

Conventional yogur

Placebo fresh cheese

Intervention Type OTHER

Conventional fresh cheese

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental milk

UNICLA milk naturally enriched in selenium and omega-3.

Intervention Type OTHER

Experimental yogur

UNICLA yogur naturally enriched in selenium and omega-3.

Intervention Type OTHER

Experimental fresh cheese

UNICLA fresh cheese naturally enriched in selenium and omega-3.

Intervention Type OTHER

Placebo milk

Conventional milk

Intervention Type OTHER

Placebo yogur

Conventional yogur

Intervention Type OTHER

Placebo fresh cheese

Conventional fresh cheese

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ÚNICLA milk ÚNICLA yogur ÚNICLA fresh cheese Conventional milk Conventional yogur Conventional fresh cheese

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of subclinical hypothyroidism
* TSH levels between 3 and 10 mIU / L
* Normal levels of free triiodothyronine ( T3) and free thyroxine (T4)
* Without previous or current treatment with levothyroxine

Exclusion Criteria

* Thyroid surgery or reception of radioactive iodine in a previous period of 12 months
* History of cardiovascular disease and / or thrombosis
* Established diagnosis or clinical suspicion of kidney or liver failure, chronic infections, blood diseases, type I diabetes and type II diabetes
* Drug treatments that affect thyroid function (corticosteroids, amiodarone, propranolol, lithium)
* Statin treatment and / or hormone replacement therapy
* Adjuvant treatment with trace elements, vitamins or antidepressant and antipsychotic drugs
* Hospitalization for serious illness or elective surgery in the past 4 weeks
* Diseases and / or treatments that affect intestinal absorption (proton pump inhibitors)
* Pregnant, planning to become pregnant or breastfeeding women
* Consumption of ω-3 PUFA type food supplements
* Intolerance and / or allergy to lactose and / or cow's milk proteins
* Any pathology that requires close control, advises against their participation or there is an inability to move independently
* Habitual residence outside the study's influence area
* Participation in another clinical trial with drugs, or in other experimental studies
* Refuse to sign the informed consent
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Galician South Health Research Institute

NETWORK

Sponsor Role collaborator

Cooperativas Lacteas Unidas

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

María Reyes Pérez Fernández

PhD Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Reyes Pérez- Fernández, PhD

Role: PRINCIPAL_INVESTIGATOR

Galicia sur sanitary research institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nursing University School of Ourense

Ourense, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

María Reyes Pérez-Fernández, PhD

Role: CONTACT

676520946

Ismael Martínez-Lede, graduate

Role: CONTACT

0034609563353

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

María Reyes Pérez-Fernández, PhD

Role: primary

0034676520946

Ismael Martínez Lede, graduate

Role: backup

0034609563353

References

Explore related publications, articles, or registry entries linked to this study.

Roibas L, Martinez I, Goris A, Barreiro R, Hospido A. An analysis on how switching to a more balanced and naturally improved milk would affect consumer health and the environment. Sci Total Environ. 2016 Oct 1;566-567:685-697. doi: 10.1016/j.scitotenv.2016.05.141. Epub 2016 May 27.

Reference Type BACKGROUND
PMID: 27239712 (View on PubMed)

Muniz-Naveiro O, Dominguez-Gonzalez R, Bermejo-Barrera A, Cocho de Juan JA, Fraga Bermudez JM, Goris Pereiras A, Lopez Santamarina A, Martinez Lede I, Valledor Puente J, Fernandez-Couto Gomez L, Bermejo-Barrera P. Selenium content and distribution in cow's milk supplemented with two dietary selenium sources. J Agric Food Chem. 2005 Dec 14;53(25):9817-22. doi: 10.1021/jf050155w.

Reference Type BACKGROUND
PMID: 16332137 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLUN-20191005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Iodine Supplementation in Obesity
NCT01985204 COMPLETED NA